Coherus BioSciences (CHRS) to Release Quarterly Earnings on Wednesday

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) will be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Coherus BioSciences (NASDAQ:CHRS - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.10. The business had revenue of $64.98 million for the quarter, compared to analysts' expectations of $57.08 million. On average, analysts expect Coherus BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Coherus BioSciences Stock Down 0.7 %

Shares of Coherus BioSciences stock traded down $0.00 on Thursday, hitting $0.75. 1,330,390 shares of the company were exchanged, compared to its average volume of 2,633,755. The company has a 50-day moving average price of $1.09 and a 200 day moving average price of $1.52. The stock has a market capitalization of $85.47 million, a price-to-earnings ratio of -0.97 and a beta of 0.65. Coherus BioSciences has a 1-year low of $0.71 and a 1-year high of $3.73.

Analysts Set New Price Targets

Several analysts have issued reports on CHRS shares. UBS Group cut Coherus BioSciences from a "buy" rating to a "neutral" rating and dropped their target price for the company from $4.00 to $1.50 in a report on Friday, August 16th. HC Wainwright restated a "buy" rating and set a $12.00 price objective on shares of Coherus BioSciences in a research report on Monday, September 16th. Finally, StockNews.com downgraded shares of Coherus BioSciences from a "buy" rating to a "hold" rating in a research note on Saturday, October 19th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, Coherus BioSciences presently has a consensus rating of "Moderate Buy" and an average price target of $7.13.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.